3 results match your criteria: "U.S. Centers for Disease Control and Preventiongrid.416738.f[Affiliation]"
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection.
Microbiol Spectr
August 2022
CDC COVID-19 Response, U.S. Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Article Synopsis
- - This study analyzed antibody concentrations in 3,067 COVID-19-unvaccinated individuals with detectable anti-SARS-CoV-2 antibodies, revealing significantly lower neutralizing and binding antibody levels compared to those seen after vaccination.
- - Approximately 88% of participants had neutralizing antibody levels associated with 70% vaccine efficacy against symptomatic infection, but only about 30% had levels indicative of 90% vaccine efficacy; binding antibody levels were even lower.
- - The findings underline the importance of vaccination for enhanced protection and recommend using standardized assays to measure antibody levels, which can inform public health decisions regarding booster doses, especially as new variants emerge.
Development of HEK-293 Cell Lines Constitutively Expressing Flaviviral Antigens for Use in Diagnostics.
Microbiol Spectr
June 2022
U.S. Centers for Disease Control and Preventiongrid.416738.f, Fort Collins, Colorado, USA.
Flaviviruses are important human pathogens worldwide. Diagnostic testing for these viruses is difficult because many of the pathogens require specialized biocontainment. To address this issue, we generated 39 virus-like particle (VLP)- and nonstructural protein 1 (NS1)-secreting stable cell lines in HEK-293 cells of 13 different flaviviruses, including dengue, yellow fever, Japanese encephalitis, West Nile, St.
View Article and Find Full Text PDFGenetic and Antigenic Characterization of an Influenza A(H3N2) Outbreak in Cambodia and the Greater Mekong Subregion during the COVID-19 Pandemic, 2020.
J Virol
November 2021
National Influenza Center of Cambodia, Virology Unit, Institut Pasteur du Cambodgegrid.418537.c, Phnom Penh, Cambodia.
Introduction of non-pharmaceutical interventions to control COVID-19 in early 2020 coincided with a global decrease in active influenza circulation. However, between July and November 2020, an influenza A(H3N2) epidemic occurred in Cambodia and in other neighboring countries in the Greater Mekong Subregion in Southeast Asia. We characterized the genetic and antigenic evolution of A(H3N2) in Cambodia and found that the 2020 epidemic comprised genetically and antigenically similar viruses of Clade3C2a1b/131K/94N, but they were distinct from the WHO recommended influenza A(H3N2) vaccine virus components for 2020-2021 Northern Hemisphere season.
View Article and Find Full Text PDF